For U.S. Healthcare Professionals Only
For U.S. Healthcare Professionals Only

CONTACT MY REP

PROPHYLACTIC USE OF ELITEK WAS PROVEN IN A PIVOTAL TRIAL TO PREVENT RISING URIC ACID IN ADULTS1

ELITEK was studied in adult patients at high and intermediate (potential) risk1

9 out of 10

adult patients were at high risk at baseline

82%

of adult patients had normal uric acid levels (≤7.5 mg/dL) at baseline

Adult patients meeting at least 1 of the following criteria were enrolled in the pivotal trial1:

HIGH RISK1-3

Aggressive lymphoma/leukemia (defined by REAL)

  • DLBCL
  • Anaplastic large cell lymphoma
  • Peripheral T-cell lymphomas
  • Burkitt lymphoma
  • Lymphoblastic lymphoma
  • CLL

AML

Elevated plasma uric acid levels (>7.5 mg/dL) at baseline

High-grade MDS with >10% bone marrow blast involvement

CML in blast crisis

INTERMEDIATE (POTENTIAL) RISK1

Aggressive lymphoma/leukemia, not limited to the REAL definition, with LDH ≥2x the upper limit of normal

Any stage III to IV lymphoma or leukemia

Stage I or II disease with bulky lymph node/tumor (>5 cm) involvement

Antihyperuricemic therapy in all 3 arms was initiated prior to anticancer therapy1,4

  • Phase 3: randomized, multicenter, open-label study in adult patients (N=275) with leukemia, lymphoma, and solid tumor malignancies at risk for hyperuricemia and TLS
  • Primary endpoint: response rate defined as the proportion of adult patients with plasmic uric acid levels maintained at ≤7.5 mg/dL between 3 and 7 days after initiation of antihyperuricemic treatment

Adult pivotal trial design1,4

Randomized, multicenter, open-label study comparing ELITEK vs allopurinol (N=275) administered 4 to 24 hours prior to anticancer therapy Randomized, multicenter, open-label study comparing ELITEK vs allopurinol (N=275) administered 4 to 24 hours prior to anticancer therapy

AML=acute myeloid leukemia; CLL=chronic lymphocytic leukemia; CML=chronic myeloid leukemia; DLBCL=diffuse large B-cell lymphoma; MDS=myelodysplastic syndrome; REAL=Revised European American Classification of Lymphoid Neoplasms.

IMPORTANT SAFETY INFORMATION

WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS

  • Hypersensitivity Reactions: ELITEK can cause serious and fatal hypersensitivity reactions including anaphylaxis. Immediately and permanently discontinue ELITEK in patients who experience a serious hypersensitivity reaction.
  • Hemolysis: Do not administer ELITEK to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue ELITEK in patients developing hemolysis. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting ELITEK.
  • Methemoglobinemia: ELITEK can result in methemoglobinemia in some patients. Immediately and permanently discontinue ELITEK in patients developing methemoglobinemia.
  • Interference with Uric Acid Measurements: ELITEK enzymatically degrades uric acid in blood samples left at room temperature. Collect blood samples in prechilled tubes containing heparin and immediately immerse and maintain sample in an ice water bath. Assay plasma samples within 4 hours of collection.

CONTRAINDICATIONS
ELITEK is contraindicated in patients with a history of anaphylaxis or severe hypersensitivity to rasburicase or in patients with development of hemolytic reactions or methemoglobinemia with rasburicase. ELITEK is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD).

ADVERSE REACTIONS
Most common adverse reactions (incidence ≥20%), when used concomitantly with anticancer therapy, are vomiting, nausea, fever, peripheral edema, anxiety, headache, abdominal pain, constipation, diarrhea, hypophosphatemia, pharyngolaryngeal pain, and increased alanine aminotransferase.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: Consider the benefits and risks of ELITEK and possible risks to the fetus when prescribing ELITEK to a pregnant woman
  • Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with ELITEK and for 2 weeks after the last dose